Our Blog

Recce Pharmaceuticals (ASX:RCE) broad spectrum antibiotic potential

15 Jul 2020 – Recce Pharmaceuticals Limited (ASX:RCE) Executive Director James Graham provides an update on positive data against a range of persistent bacteria using the company’s synthetic antibiotic RECCE 327, commencement of Phase I human clinical trial in 2H20 and key priorities.

Source: Finance News Network

Share this post